Vimarsana
Biggest News Aggregation in the World

Page 38 - Live Webcast News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Live Webcast. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Live Webcast Today - Breaking & Trending Today

Tata Motors : Details of conference call on financial results for Q4FY2023 of Tata Motors Limited ('the Company') with the investor / analysts - Form 6-K - Vimarsana News

Tata Motors : Details of conference call on financial results for Q4FY2023 of Tata Motors Limited ('the Company') with the investor / analysts - Form 6-K

Details of conference call on financial results for Q4FY2023 of Tata Motors Limited with the investor / analysts May 1, 2023, Mumbai: With reference to our filing dated April... | May 1, 2023

Mattel : 2023-Q1 Press Release | MarketScreener - Vimarsana News

Mattel : 2023-Q1 Press Release | MarketScreener

MATTEL REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS First Quarter 2023 Highlights Versus Prior Year Net... | April 26, 2023

Genius : THE PROPOSED CAPITAL REDUCTION AND DISTRIBUTION OF SHARES IN ENTREPRENEUR RESORTS LIMITED TO SHAREHOLDERS - Form 6-K - Vimarsana News

Genius : THE PROPOSED CAPITAL REDUCTION AND DISTRIBUTION OF SHARES IN ENTREPRENEUR RESORTS LIMITED TO SHAREHOLDERS - Form 6-K

THE PROPOSED CAPITAL REDUCTION AND DISTRIBUTION OF SHARES IN ENTREPRENEUR RESORTS LIMITED TO SHAREHOLDERS 1. ... | April 12, 2023

Investegate |Indivior PLC Announcements | Indivior PLC: Notice of Q1 Results - Vimarsana News

Investegate |Indivior PLC Announcements | Indivior PLC: Notice of Q1 Results

Investegate announcements from Indivior PLC, Notice of Q1 Results

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 - Vimarsana News

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients... | April 11, 2023